Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Investigating the role of the intercrypt goblet cells in inflammatory bowel diseases.

Project description

The role of mucus in inflammatory bowel diseases

The gut mucus layer produced by goblet cells plays a crucial role in shielding our intestines from inflammation-triggering microbiota. Imbalances favouring mucus-degrading bacteria are linked to inflammatory bowel diseases, like ulcerative colitis, where the mucus barrier falters. With the support of the Marie Skłodowska-Curie Actions programme, the GAP project will merge animal and human studies to demystify the molecular glitches that diminish protective goblet cells. Building on expertise spanning microbiota, metabolism, and nutrition, the project seeks to fortify our understanding of this vital point of defence, aiming to transform it into therapeutic solutions for enhanced gut health.

Objective

The mucus layer produced by the goblet cells (GCs), provides the barrier between the microbiota and the intestine preventing the occurrence of the inflammation process. Indeed, alteration in microbiota towards mucus degrading bacteria, are often associated with impaired mucus barrier properties and inflammatory bowel diseases, such as ulcerative colitis (UC). Although, the exact mechanisms behind UC are not understood, defects in luminal compartmentalisation of bacteria by mucus could play a major role in this disease etiology. The recent identification of the intercrypt goblet cells (icGCs) population has improved the understanding and modified the model of the mucus layer formed on the epithelial surface. The icGCs secrete mucus that differs from mucus produced by crypt-residing GCs, and both are required to provide a protective mucus barrier function. Deficient intercrypt mucus secretion or reduced icGC numbers leads to disruption of the mucus layer with an impaired organization at the mucus surface which correlates with increased colitis susceptibility. However, the mechanisms behind icGC defects still remain unclear. In this project, I will combine both animal and human studies to decipher the molecular mechanisms behind the loss of icGCs that occurs during UC and elucidate to what extent a deviated microbiota is involved in their modulation. The data from the research programme will underpin the development of future therapeutic strategies to improve human health. The fellow has experience in microbiota research, metabolism and nutrition. With this fellowship, he will have the opportunity to develop skills in mucin biology, evaluation of the mucus properties and imaging experiments. This grant will enable the fellow to develop his current skill set to include methodologies and approaches so that the microbiota features can be placed within a new biological context.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

UNIVERSITEIT UTRECHT
Net EU contribution
€ 187 624,32
Address
HEIDELBERGLAAN 8
3584 CS Utrecht
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)